Stock vs Stock Comparison

Addus HomeCare Corporation vs AbCellera Biologics Inc.

ADUS wins the Tale of the Tape 5–1.

ADUS
ABCL

🏆 Tale of the Tape

51
ADUSABCL
6.7%Profitability (Net Margin)-194.9%
19.1xValuation (P/E)
8.6%Efficiency (ROIC)-12.4%
7/9Health (Piotroski F)4/9
23.2%Growth (Rev YoY)160.6%
0.32xBalance Sheet (D/E)0.40x

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricADUSABCL
Market Cap$1.9B
P/E Ratio19.1x
Forward P/E13.4x
P/B1.66x
Dividend Yield
Beta0.96

Quantitative Metrics

MetricADUSABCL
DCF Fair Value$78.70
DCF Upside
Piotroski F7/94/9
Altman Z
Beneish M-2.29
FCF Yield
Net Debt/EBITDA0.2x
ROIC8.6%-12.4%
WACC
ROIC – WACC
Gross Margin32.5%
Net Margin6.7%-194.9%
Rev Growth YoY23.2%160.6%
Sharpe (1Y)
Max Drawdown 3Y
FCF Payout Ratio

ADUS Price

Loading chart...

ABCL Price

Loading chart...

ETF Exposure

ADUS found in:

XHS1.63%
SLYG0.13%
SPSM0.10%
SLYV0.07%
VHT0.03%
SPTM0.00%

ABCL found in:

GWX0.09%
SPDW0.01%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ADUS vs ABCL: Head-to-Head Analysis

Addus HomeCare Corporation (ADUS) and AbCellera Biologics Inc. (ABCL) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ADUS leads 5–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ADUS generates a return on invested capital (ROIC) of 8.6% compared to ABCL's -12.4%. This suggests ADUS is more effective at deploying capital to generate shareholder returns.

ADUS appears in 6 ETFs tracked by SecuritiesDB, while ABCL appears in 2 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ADUS or ABCL?

Our quantitative analysis compares ADUS and ABCL across nine fundamental dimensions. ADUS wins the Tale of the Tape 5–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ADUS and ABCL correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.